DOCSLIB.ORG

Of the Royal College of Pathologists

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Of the Royal College of Pathologists The Bulletin of the Royal College of Pathologists Number 191 July 2020 SPECIAL EDITION: Pathology and COVID-19 The role of genomics in shaping the response Cytology and the pandemic Experiences of NHS Nightingale Death certification Establishing convalescent plasma therapy Caring for the deceased Testing in the devolved nations Our COVID-19 seminars Also in this issue: The Royal College of Pathologists Haematology workforce challenges Pathology: the science behind the cure Going digital: training and exams Kate Gould: an appreciation The Royal College of Pathologists CONTENTS Pathology: the science behind the cure July 2020 NuMBER 191 EDITORIALS 114 INTERNATIONAL 150 From the Editor 114 Challenges for pathology laboratories during From the President 115 the pandemic: the view from Australia 150 PATHOLOGY AND COVID-19 117 Reorganisation of mobile blood collections in the age of social distancing 152 A new plague year 117 The role of viral genomics in shaping the TRAINING 154 response to the pandemic 118 FRCPath examinations during the COVID Nightingale tales 121 pandemic 154 The journey from Oxford medical school to Digital pathology and safe workplace the world’s largest ICU 124 station awareness 157 Cytology and the pandemic 125 Creating e-learning modules for undergraduate Establishing convalescent plasma as an medical students 159 effective therapy 126 Digital pathology validation for trainees: 160 Healthcare scientists in pathology: the CLINICAL EFFECTIVENESS 162 challenges of responding to the virus 128 What does patient safety in pathology Death certification: lessons learned within mean to me? 162 the hospital setting 130 Antibiotic prescribing following a positive Caring for deceased patients at the NHS Clostridioides difficile result 163 Nightingale mortuary 131 PEOPLE 166 A chaplaincy view from a multi-faith university hospital community 133 Appreciation: Professor Frances Kate Gould 166 Appreciation: Dr Denis Raymond Stanworth 167 COLLEGE NEWS 134 Appreciation: Dr Michael Gerald Rinsler 168 The RCPath Learning Programme: Appreciation: Professor Mohammed Sami the COVID-19 pandemic 134 Shousha 169 Moving to the new College premises 135 Archive of eminent pathologist Sir Lionel RCPath Consulting 137 Whitby deposited at Downing College 170 ON THE AGENDA 138 Deaths reported to Council 172 Challenges for the haematology workforce 138 Consultants: new appointment offers 172 Tackling haematology scientific workforce REVIEWS 174 challenges 140 The Royal College of Pathologists Book reviews 174 6 Alie Street, London E1 8QT The journey to pathology 3.0: more on New report calls for collaboration to ‘bricks’ and ‘clicks’ 141 improve cancer diagnostics 176 T: 020 7451 6700 E: [email protected] SHARING OUR SUBJECT 144 Charming snakes: a seminar on reptiles 177 www.rcpath.org School’s out but the Schools Science Highlighting chemical pathology Conference must go on 144 and metabolic medicine overseas 178 President Professor Jo Martin Vice Presidents Dr Rachael Liebmann REGIONAL 146 Letter: Reporting of race in autopsy reports 179 Dr Tim Littlewood COVID-19 and the devolved nations 146 On the cover: An illustration Professor Shelley Heard of the COVID-19 virus. Registrar Dr Lance Sandle Highlighting UK workforce concerns 148 Assistant Registrar Dr Esther Youd Treasurer Dr Andrew Boon CEO Daniel Ross Bulletin Editor Dr Shubha Allard Disclaimer: Authors’ views are personal and are not indicative of College policy, except when College Officers write in their official capacity. Errors or admissions are the responsibility of the Production Editor Stacy Baxter authors alone. Advertisements are paid for by external agencies and do not indicate endorsement or otherwise by the College. Editorial & Digital Manager Rob Hucker www.rcpath.org Number 191 July 2020 113 EDITORIAlS EDITORIALS From the President Change all around us the skills for interpretation and quality control, and From the Editor It has been a time of enormous change for everyone, the key infrastructure and data connectivity that all over the world. We have changed what we do we need, rather than just numbers of tests being Welcome to our first digital College Bulletin! The impressive, with greater inclusion and engage- and how we do it, including the services in which performed. We have the support of 22 organisa- theme, understandably, is COVID-19 – a topic ment. While travel is curtailed we can certainly we work, in an incredibly short period of time and tions and the strategy has been very well received that has totally refashioned how we conduct our still push boundaries and reach out to colleagues at a rapid pace with considerable personal effort. by our stakeholders. We have had excellent media working and personal lives. Out of adversity and to work together. The pandemic resulted in a We have done this at a time when there has been coverage and interest and support from politicians. significant personal loss has come some good, with fundamental rethink of working arrangements in huge change in our own circumstances in the face Feedback from the government has been positive the pandemic being the unlikely enabler of inno- many countries so that we can share lessons (p150 of personal loss or significant difficulties. Thank and we are determined to ensure it informs policy Professor Jo Martin vation and novel ideas. Contrary to my initial fears and p152), even if significantly lower numbers of you for all you continue to do for our patients and development in the UK. Do have a look at it if you that authors would be unable to contribute, this is COVID-19 cases were encountered than in the UK. for our profession. We really value your skills, your have not had a chance so far. It’s a strong message an extraordinary ‘bumper’ edition and I have been The strengthening of IT with remote working effort and your enormous dedication. in a clear format. delighted by the immense breadth of the contribu- and greater interconnectivity will hopefully also We have also made significant and large-scale The College has been heavily involved in the Dr Shubha Allard tions received. help support greater digitisation of pathology changes at the College. You will have seen the speed development and championing of an innovative The introduction to the theme by David Jenkins and transformation of services across organisa- with which we have been responding to the need crowdsourcing platform ‘Testing Methods 2020’. (p117) eloquently captures the essence of key tional boundaries (p141). However, the workforce for information-specific guidance across a whole This has posed specific challenges for the commu- events and milestones as the pandemic unfolded. remains our greatest resource, with a progressive range of issues during the epidemic. This has been nity of pathologists, laboratory professionals and A heady mix of articles on COVID-19 covers approach needed to the development of medical achieved by the efforts of our Specialty Advisory industry related to COVID-19. Examples have molecular science and the role of whole genome and scientific staff. Clearly there are major chal- Committees and Chairs and our Communications included extraction-free rtPCR methods, alterna- sequencing in mapping global progression (p118), lenges ahead and much still to do (p138 and p140). directorate, with exceptional responsiveness to tives to swab methods and multiplexing. A new finishing with the challenges of supporting the The increasing focus on diversity and inequality professional needs. Some of the other changes were challenge has also just been launched on ‘greener bereaved in a multi-faith university chaplaincy is timely and we must surely now pursue this already planned, but have now been accelerated by testing’ that is being championed by Dr Esther (p133). Along the way we hear about the significant dialogue across our specialties. I do look forward the advent of COVID-19 – a digital Bulletin being Youd, our Assistant Registrar, who is also our achievements of setting up a new pathology service to hearing thoughts and comments on reporting of one of these. The era of posted journals is being RCPath Trustee Board sustainability champion. (virtually overnight) to support the emergency race at autopsy (p179). Is it time to review practice superseded by the era of digital media. This is good This has suggestions on plastic-free swabs, and we field Nightingale hospital at the Excel site (pp121 and recommend change? for both the finances and the environment, and are looking forward to ways in which we might be and p131), addressing the increased demands for I have been really pleased with the increasing especially good during the epidemic. I do know able to reduce our plastic usage for the transport of death certification in adverse circumstances (p30) number of books coming our way and the ready that there will be nostalgia for the paper format for samples. Do get involved to help spread great ideas together with the impressive contribution of many volunteers willing to review these, hopefully some, but I hope that you will enjoy this version and new ways of working! healthcare scientists across a breadth of specialties igniting your interest in the topics covered. We equally. As we move into the next phase of dealing (p128). hope to maintain this trend and are happy to with the epidemic, and as we try to build back up The need for high-quality research to support receive your suggestions and input. Virtual meetings and education to some form of normality in our health services, the introduction of any new therapies, however We must sadly remember colleagues we have We have moved to online meetings for all our I am acutely aware that many of the problems persuasive retrospective surveys and anecdotal use lost and acknowledge their significant achieve- committees, Council and Trustee Board and will around lack of workforce, especially in transfu- may seem, is emphasised in an article (p126) on the ments (ppp166–169), including Kate Gould, who continue with the virtual format for the vast sion and histopathology, are still there.
Load more

Recommended publications
  • (MGH) COVID-19 Treatment Guidance
    Version 8.0 4/28/2021 10:00AM © Copyright 2020 The General Hospital Corporation. All Rights Reserved. Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance This document was prepared (in March, 2020-April, 2021) by and for MGH medical professionals (a.k.a. clinicians, care givers) and is being made available publicly for informational purposes only, in the context of a public health emergency related to COVID-19 (a.k.a. the coronavirus) and in connection with the state of emergency declared by the Governor of the Commonwealth of Massachusetts and the President of the United States. It is neither an attempt to substitute for the practice of medicine nor as a substitute for the provision of any medical professional services. Furthermore, the content is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment. The information herein should be adapted to each specific patient based on the treating medical professional’s independent professional judgment and consideration of the patient’s needs, the resources available at the location from where the medical professional services are being provided (e.g., healthcare institution, ambulatory clinic, physician’s office, etc.), and any other unique circumstances. This information should not be used to replace, substitute for, or overrule a qualified medical professional’s judgment. This website may contain third party materials and/or links to third party materials and third party websites for your information and convenience. Partners is not responsible for the availability, accuracy, or content of any of those third party materials or websites nor does it endorse them.
    [Show full text]
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • Impact of SARS-Cov-2 Variant on the Severity of Maternal Infection and Perinatal Outcomes: Data from the UK Obstetric Surveillan
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.22.21261000; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. Nicola Vousden PhD1, Rema Ramakrishnan PhD1, Kathryn Bunch MA1, Edward Morris MD2, Nigel Simpson MBBS3, Christopher Gale PhD4, Patrick O’Brien MBBCh,2,5, Maria Quigley MSc1, Peter Brocklehurst MSc6, Jennifer J Kurinczuk MD1, Marian Knight DPhil1 1National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK 2Royal College of Obstetricians and Gynaecologists, London, UK 3Department of Women's and Children's Health, School of Medicine, University of Leeds, UK 4Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, London, UK 5Institute for Women’s Health, University College London, London, UK 6Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, UK *Corresponding author: Marian Knight National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK 01865 289700 [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.07.22.21261000; this version posted July 25, 2021.
    [Show full text]
  • An Examination of COVID-19 Medications' Effectiveness
    healthcare Review An Examination of COVID-19 Medications’ Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review Mahmoud Al-Masaeed 1,* , Mohammad Alghawanmeh 2, Ashraf Al-Singlawi 3 , Rawan Alsababha 4 and Muhammad Alqudah 1 1 Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia; [email protected] 2 Faculty of Pharmacy, Philadelphia University, Amman 19392, Jordan; [email protected] 3 Independent Scholar, Amman 11731, Jordan; [email protected] 4 School of nursing and Midwifery, Western Sydney University, Sydney 2560, Australia; [email protected] * Correspondence: [email protected] Abstract: Background: The review seeks to shed light on the administered and recommended COVID- 19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review’s literature search was guided by the WHO Citation: Al-Masaeed, M.; solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings Alghawanmeh, M.; Al-Singlawi, A.; indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been Alsababha, R.; Alqudah, M. An useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the Examination of COVID-19 need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, Medications’ Effectiveness in minerals, and supplements has been linked to increased immunity and thus offering the body a Managing and Treating COVID-19 fighting chance. Nevertheless, antibiotics do not correlate with improving patients’ wellbeing and Patients: A Comparative Review.
    [Show full text]
  • Official Report of This Meeting
    COVID-19 Committee Thursday 18 February 2021 Session 5 © Parliamentary copyright. Scottish Parliamentary Corporate Body Information on the Scottish Parliament’s copyright policy can be found on the website - www.parliament.scot or by contacting Public Information on 0131 348 5000 Thursday 18 February 2021 CONTENTS Col. CITIZENS PANEL ................................................................................................................................................ 5 SUBORDINATE LEGISLATION............................................................................................................................. 26 Personal Protective Equipment (Temporary Arrangements) (Coronavirus) (Scotland) Regulations 2021 (SSI 2021/50) ............................................................................................................. 26 Health Protection (Coronavirus) (Restrictions and Requirements) (Local Levels) (Scotland) Amendment (No 16) Regulations 2021 [Draft] ........................................................................................ 26 COVID-19 COMMITTEE 6th Meeting 2021, Session 5 CONVENER *Donald Cameron (Highlands and Islands) (Con) DEPUTY CONVENER Monica Lennon (Central Scotland) (Lab) COMMITTEE MEMBERS *Willie Coffey (Kilmarnock and Irvine Valley) (SNP) *Maurice Corry (West Scotland) (Con) *Annabelle Ewing (Cowdenbeath) (SNP) *John Mason (Glasgow Shettleston) (SNP) *Stuart McMillan (Greenock and Inverclyde) (SNP) *Mark Ruskell (Mid Scotland and Fife) (Green) *Beatrice Wishart (Shetland Islands) (LD)
    [Show full text]
  • Pandemic Planning , File Type: PDF, File Size
    July 2021 Dear ATISN 15194 – Pandemic Planning Thank you for your request to the Welsh Government for information under the Freedom of Information Act (2000) received on 03 June 2021. I have interpreted your requested information regarding pandemic planning as follows: 1. What plans were in place for a potential future pandemic before the COVID19 crisis began? 2. What conversations were had at ministerial level, before COVID19, about the potential of a future pandemic? 3. What plans are now in place for a future pandemic, if any? Our Response What plans were in place for a potential future pandemic before the COVID-19 crisis began? Wales, together with the rest of the UK, has been preparing its response to an influenza pandemic for many years. In 2007, Wales participated in the UK level (Tier 1) pandemic flu exercise Winter Willow, which led to the development of the 2007 National Framework for Responding to an Influenza Pandemic. This framework was used to support our Welsh Government response to the 2009 H1N1 Swine Flu pandemic. Although the H1N1 pandemic was not as severe as initially predicted, it did identify areas for further planning and Wales worked with the other UK governments to put in place the UK Influenza Preparedness Strategy 2011. This UK Strategy was agreed by the Health Ministers of all four nations. In 2016, our pandemic influenza plans were tested during Exercise Cygnus. The subsequent lessons identified were taken forward into an ongoing review of pandemic preparedness led by the UK Cabinet Office and Department of Health and Social Care.
    [Show full text]
  • COVID-Clinical-Update.Pdf
    COVID-19 Update Jorge Mera, MD Whitney Essex, APRN Questions • I have heard that the only thing that will end this pandemic is acquisition of immunity. That means either natural or by vaccination, therefore, in the absence of vaccination, we should be encouraging natural immunity (infection with recovery) rather than advocating avoidance. Any chosen path will result in casualties. however, our current path of avoidance is drawing out the process and hurting our nation. Please comment. • Prescriptions for zithromax and hydroxychloroquine have skyrocketed across the nation. Is there any role for these medications for outpatients, either prophylactically or for treatment? Please also discuss other treatments being advocated such as zinc. Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries • Non-pharmacological interventions (NPI) have been the mainstay for controlling the COVID-19 pandemic. • While NPIs are effective in preventing health systems overload, these long-term measures are likely to have significant adverse economic consequences • Many countries are currently considering to lift the NPIs • Dynamic NPIs, with intervals of relaxed social distancing, may provide a more suitable alternative, • But the ideal frequency and duration of intermittent NPIs, and the ideal “break” when interventions can be temporarily relaxed, remain uncertain • Multivariate prediction model, based on up-to-date transmission and clinical parameters, to simulate outbreak traJectories in 16 countries, from diverse regions and economic categories. • In each country, we then modelled the impacts on intensive care unit (ICU) admissions and deaths over an 18-month period for following scenarios: 1. No intervention 2. Consecutive cycles of mitigation measures followed by a relaxation period 3.
    [Show full text]
  • Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews
    Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews RAPID REVIEW – July 13th 2020. (The information included in this review reflects the evidence as of the date posted in the document. Updates will be developed according to new available evidence) Disclaimer This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. Yet, recognizing that there are numerous ongoing clinical studies, PAHO will periodically update these reviews and corresponding recommendations as new evidence becomes available. 1 Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews Take-home messages thus far: • More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. In this review we examined 26 therapeutic options. • Preliminary findings from the RECOVERY Trial showed that low doses of dexamethasone (6 mg of oral or intravenous preparation once daily for 10 days) significantly reduced mortality by one- third in ventilated patients and by one fifth in patients receiving oxygen only. The anticipated RECOVERY Trial findings and WHO’s SOLIDARITY Trial findings both show no benefit via use of hydroxychloroquine and lopinavir/ritonavir in terms of reducing 28-day mortality or reduced time to clinical improvement or reduced adverse events. • Currently, there is no evidence of benefit in critical outcomes (i.e. reduction in mortality) from any therapeutic option (though remdesivir is revealing promise as one option based on 2 randomized controlled trials) and that conclusively allows for safe and effective use to mitigate or eliminate the causative agent of COVID-19.
    [Show full text]
  • 27Th APRIL 2020
    27th APRIL 2020 19 COVID-19 REPORT SUMMARY • The number of confirmed deaths as a result of COVID-19 has now passed 200,000 with Johns Hopkins University confirming almost 2,980,053 cases worldwide. • On 25th April, the UK became the fifth country in the world to record 20,000 hospital deaths as a result of COVID- 19. The UK death toll currently stands at 20,732. • Several Muslim majority countries have now begun to soften COVID-19 measures in preparation for the holy month of Ramadan with Saudi Arabia, Egypt and Algeria all shortening curfews that had been in place. • Multiple US States and European countries have begun to ease lockdown restrictions having instituted plans to begin reopening shops. • The World Health Organisation has warned that Africa could see as many as 10 million cases of COVID-19 within three to six months. In the last 10 days alone, the continent has seen a 40% rise in new COVID-19 cases. • A second wave of locusts has descended on East Africa and the swarm is estimated to be 20 times bigger than the first invasion at the end of 2019. Amidst the COVID-19 global lockdown, pesticides and bio-pesticides usually sourced from countries such as Japan, Morocco and the Netherlands, have become more expensive and harder to obtain. Further to this, protective clothing worn when using pesticides have been taken for those combating this coronavirus outbreak. • The World Health Organisation has warned against introducing ‘immunity passports’ for people who have recovered from the COVID-19 virus, citing that ‘there is currently no evidence that people who have recovered from Covid-19 and have antibodies are protected from a second infection’.
    [Show full text]
  • COVID-19/SARS-Cov2: an Exploration
    COVID-19/SARS-CoV2: An Exploration How we act now INTERACTIVE DOWNLOADABLE PDF will build the future for our children An urgent invitation: • To question all that is happening before the chance is lost • To explore broader science, views and statistics • To research further A compilation of links to resources that will: • Help you to navigate the current situation • Help you to make informed decisions • Promote open debate and explore different views • Offer a starting point for further research • Introduce just the tip of the iceberg of the wealth of knowledge we can explore Photo by Monica Gozalo on Unsplash.com • June 2021 COVID-19/SARS-CoV2: An Exploration PLEASE NOTE: Any text you see coloured orange with an underline throughout this document, will be clickable live links to internal Sections or Pages within this document, or go to external reference websites. INTRODUCTION In response to the remarkable times we are living in, we have created this shareable, downloadable, interactive PDF Exploration document ( also found on-lineHERE ), a gathering of our extensive research into the covid pandemic and its effects on us all. We hope that it will enable and inspire you to research further if you choose to. We respect and appreciate that some of what you read and explore may challenge views you hold to be true at the moment, but we believe there are significant questions that need asking about the Covid19 narrative as it is. We all wish to make choices that will enable a full and healthy life for ourselves, our communities and our children, and that are right for now and for the future.
    [Show full text]
  • RECOVERY Protocol V12 (2020-12-16)
    RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY) Background: In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, low-dose corticosteroids, and Hydroxychloroquine (which has now been done). A World Health Organization (WHO) expert group issued broadly similar advice. These groups also advised that other treatments will soon emerge that require evaluation. Eligibility and randomisation: This protocol describes a randomised trial among patients hospitalised for COVID-19. All eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs colchicine vs corticosteroids (children only) vs intravenous immunoglobulin (children only). In a factorial design (in the UK alone), eligible patients are allocated simultaneously to no additional treatment vs convalescent plasma vs synthetic neutralising antibodies (REGN-COV2). Separately, all participants aged 18 years or older will be allocated to either aspirin vs control. The study allows a subsequent randomisation for patients with progressive COVID-19 (evidence of hyper-inflammatory state): No additional treatment vs tocilizumab. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms. Adaptive design: The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The most important task for the DMC will be to assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies.
    [Show full text]
  • How the Nations Should Gear up for Future Pandemics?
    Electronic supplementary material: The online version of this article contains supplementary material. Cite as: Issac A, Vijay VR, Krishnan N, Jacob J, Stephen S, Radhakrishnan RV, Dhan- © 2021 THE AUTHOR(S) dapani M. How the nations should gear up for future pandemics? J Glob Health JOGH © 2021 ISGH 2021;11:03075. How the nations should gear up for future pandemics? VIEWPOINTS Alwin Issac1, VR Vijay1, Nadiya Krishnan1, Jaison Jacob1, Shine Stephen1, Rakesh Vadakkethil Radhakrishnan1, Manju Dhandapani2 1College of Nursing, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India 2National Institute of Nursing Education, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India ealth authorities from the city of Wuhan, China, informed World Health Organization (WHO) about an increase in pneumonia cases of unknown origin on December 31, 2019. Health authorities in China Hdetected novel coronavirus as the causative agent for the pneumonia cases and the virus was initially named “2019-nCoV”, which was later renamed as coronavirus disease 2019 (COVID-19). Owing to the virus virulence and its contagious nature, WHO declared novel coronavirus outbreak a public health emergency of international concern. With the steep rise in number of people infected with the virus outside China, WHO stated the eruption as a pandemic on March 11, 2020 [1]. Owing to the plight of wildlife habitat, poor health system, and global connectivity, COVID-19 wouldn’t be the last time a virus would jump from animal into humans To increase pandemic resil- and endanger humanity. The ever-rising trend of globalization and human migra- ience, nations must adhere to tion for trade, commerce, and tourism across the national borders has made it easy the fundamentals of universal for an outbreak to progress to a pandemic.
    [Show full text]